Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05208125
Other study ID # BCN03
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date March 30, 2022
Est. completion date December 18, 2023

Study information

Verified date May 2024
Source IrsiCaixa
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

BCN03 is a Single-site, randomized, double-blind, placebo-controlled, phase I study to evaluate the safety, tolerability, immunogenicity, and efficacy of a vaccine regimen that includes a sequence of the T- and B-cell immunogens ChAdOx1.HTI and MVA.HTI and ConM SOSIP.v7 gp140 adjuvanted with MPLA liposomes in 30 virologically-suppressed ART-treated HIV-1 positive individuals.


Description:

Participants will be randomized to receive either the combined regimen with T- and B-cell immunogens (CSSMS) or placebo (PPPPP) in a double-blinded fashion at a ratio of 2:1. Safety and immunogenicity of the combined T- and B-cell regimen will be measured up to week 30 (2 weeks after last ConM SOSIP.v7/placebo administration). At week 30, all participants will undergo an ATI of 24 weeks of duration. At visit week 54 (End-of-ATI visit), or before according to pre-specified criteria, ART will be resumed. Efficacy endpoints will be measured at 12 and 24 weeks of ATI (study visits week 42 and 54). After ART resumption, participants will be followed during an additional safety period of 12 weeks (study visit week 66, End-of-Study visit). Treatment allocation will remain blinded until week 54 (End-of-ATI visit).


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date December 18, 2023
Est. primary completion date March 30, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: 1. Males and females aged at least 18 years on the day of screening and no greater than 60 years on the day of the first IMP administration. 2. Confirmed HIV-1 infection. 3. Optimal virological suppression for at least 2 years prior to the screening visit, defined as maintained pVL <50 cop/ml allowing for isolated blips (non-consecutive 50-200 copies/mL) 4. Being on the same ART regimen within at least 4 weeks prior to screening visit. 5. CD4 count = 500 cells/mm3 at the screening visit. 6. Nadir CD4 count = 350 cells/mm3. Lower counts at the moment of acute HIV-1 infection will be allowed only if appropriate immune recovery was followed after ART initiation and ART was not initiated within first 6 months after estimated time of HIV-1 acquisition. 7. Willing and able to be adherent to their ART regimen for the duration of the study. 8. Willing to comply with the requirements of the protocol and available for follow-up for the planned duration of the study. 9. In the opinion of the Principal Investigator or designee, the candidate has understood the information provided and capable of giving written Informed Consent. 10. If heterosexually active female of childbearing potential(1), using an effective method of contraception (hormonal contraception, intra-uterine device (IUD), or anatomical sterility in self or partner(1) from 14 days prior to the first IMP administration and commit to use it until four months after the last IMP administration or until her pVL is <50 copies/mL in two-consecutive determinations after ART resumption, whichever is later. All female candidates of childbearing potential who are not heterosexually active at screening, must agree to utilise an effective method of contraception if they become heterosexually active during the study. 11. If heterosexually active male, regardless of reproductive potential, sterilized or agree on the use of an effective method of contraception by his female partner (hormonal contraception, intra-uterine device (IUD), or anatomical sterility(2) from the day of the first IMP administration until four months after the last IMP administration or until his pVL is <50 copies/mL in two-consecutive determinations after ART resumption, whichever is later. All male candidates who are not heterosexually active at screening, must agree to utilise an effective method of contraception if they become heterosexually active during the study. 12. Il female, willing to undergo urine pregnancy tests at the designated time points. 13. Willing to accept blood draws and collect stool at time points specified in the Schedule of Events (Appendix VII). 14. Willing to forgo donating blood, eggs, or sperm from the first IMP administration until four months after last IMP administration or until his or her pVL is <50 copies/mL in two-consecutive determinations after ART resumption, whichever is later. - (1) A woman will be considered of childbearing potential if not permanently sterilized nor postmenopausal. Permanent sterilization methods include tubal ligation, hysterectomy and bilateral oophorectomy. Postmenopausal is defined as 12 months with no menses without an alternative medical cause. - (2) Condom use nor diaphragm are considered as an additional method of contraception only and cannot be the only method of contraception used as not been considered an effective method by the Clinical Trial Facilitation Group (CTFG) guidelines. Exclusion Criteria: 1. If female, pregnant or planning a pregnancy during the study and until at least four months after the last IMP administration or until her pVL is <50 copies/mL in two-consecutive determinations after ART resumption, whichever is later; or lactating. 2. ART initiated within 6 months from the estimated time of HIV-1 acquisition documented by immediate ART initation after a) an HIV-1 documented seroconversion (<180 days), b) an HIV-1 diagnose with negative or indeterminate western blot test or positive p24 antigenemia and/or c) presenting with symptoms suggestive of acute retroviral syndrome. 3. When available, pre-ART genotypic data that demonstrates the presence of clinically significant drug resistance mutations that could prevent the construction of a viable ART regimen post-treatment interruption. 4. Reported periods of suboptimal adherence to ART or suboptimal ART regimens (dual therapy allowed as switch-regimens if sustained viral uppression pVL<50 copies/ml is documented). 5. History of past ART interruptions longer than 2 weeks. 6. Participation in another clinical trial that involves a treatment intervention (active arm) within 12 weeks of study entry (at screening visit). 7. Any AIDS-defining disease or progression of HIV-related disease. 8. History of autoimmune disease. 9. History or clinical manifestations of any physical or psychiatric disorder which could impair the subject's ability to complete the study. 10. Receipt of approved vaccines within 3 weeks of study entry(1) 11. Known hypersensitivity to any component of the IMP formulation, or severe or multiple allergies to drugs or pharmaceutical agents. 12. Previous immunisation with any experimental immunogens. 13. Potential participant received or plans to receive: 1. licensed live attenuated vaccines - within 28 days before or after planned administration of the first or subsequent study vaccinations. For details regarding COVID-19 vaccines, see bullet c and d below. 2. other licensed (not live) vaccines - within 14 days before or after planned administration of the first or subsequent study vaccinations. For details regarding COVID-19 vaccines, see bullet c and d below. 3. Recombinant viral vectored COVID-19 vaccines or live attenuated COVID-19 vaccines, either licensed or authorized for emergency use (eg. Emergency Use Authorization [EUA], Emergency Use Listing [EUL] or similar program) - within 28 days before or after planned administration of the first or subsequent study vaccinations. 4. Other COVID-19 vaccines than the ones specified in bullet c (eg. mRNA vaccines, protein-based vaccines) either licensed or authorized for emergency use (eg. EUA, EUL or similar program) - within 14 days before or after planned administration of the first or subsequent study vaccinations. 14. Receipt of blood products within 3 months of study entry. 15. Treatment for cancer or lymphoproliferative disease within 1 year of study entry. 16. Current or recent use (within last 3 months) of interferon or systemic corticosteroids or other immunosuppressive agents (use on inhaled steroids for asthma or topic steroids for localized skin conditions are permitted). 17. Any other current or prior therapy which, in the opinion of the investigator, would make the individual unsuitable for the study or influence the results of the study. 18. Any laboratory abnormalities including: Hematology - Hemoglobin < 10.0 g/dl - Absolute Neutrophil Count = 1,000 /mm3 (= 1 x 109/L) - Absolute Lymphocyte Count = 600 /mm3 (= 0.6 x 109/L) - Platelets =100,000 /mm3, = 550,000 /mm3 (= 100 /L, = 550 /L) Biochemistry - Creatinine > 1.3 x ULN - Aspartate aminotransferase (AST) > 2.5 x ULN - Alanine aminotransferase (ALT) > 2.5 x ULN Microbiology - Positive for hepatitis B surface antigen, - Positive for hepatitis C antibody, unless confirmed clearance of HCV infection (spontaneous or following treatment) - Positive serology indicating active syphilis requiring treatment(2) 19. Refusal to an eventual ART interruption within the scope of the study objectives(3). - (1)Efforts will be made to ensure all participants included are updated on their Hepatitis A, Hepatitis B and Pneumococcal vaccinations before enrolment. Seasonal Flu vaccinations or other required vaccinations will be scheduled to avoid the 3 weeks preceding and following IMP administrations and the first 12 weeks of ATI. - (2) Cases in which positive RPR titres are detected but syphilis has been confirmed to have been properly treated will be allowed into the study if treatment has been given >4 weeks prior to study entry/IMP administration. - (3)A questionnaire related to ART interruption will be answered by the candidate during the screening visit to be able to address Expectations and Worries in a timely manner to reduce the risk of participants lost to follow-up during the study.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
ChAdOx1.HTI at week 0, ConM SOSIP.v7 at weeks 4, 12 and 28, and MVA.HTI at week 22 (CSSMS).
Intramuscular administration of 1 x ChAdOx1.HTI (5x1010 Vp), 3 x ConM SOSIP.v7 (100µg) adjuvanted with MPLA liposomes (500µg), and 1 x MVA.HTI (2x108pfu)
Other:
Normal saline solution
Intramuscular administration of normal saline solution

Locations

Country Name City State
Spain Germans Trias i Pujol Hospital Badalona Barcelona

Sponsors (5)

Lead Sponsor Collaborator
IrsiCaixa Beatriz Mothe Pujadas PhD,MD, José Moltó Marhuenda, PhD, MD, Lucía Bailón Álvarez, MD, Susana Benet Garrabé, PhD,MD

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Local IMP-related AEs of Grade 3 and 4 Proportion of participants that develop Grade 3 or 4 local IMP-related AEs, based on the DAIDS scale From first administration up to week 30 (i.e., start of ATI, 2 weeks after last administration).
Primary Systemic IMP-related AEs of Grade 3 and 4 Proportion of participants that develop Grade 3 or 4 systemic IMP-related AEs, based on the DAIDS scale From first administration up to week 30 (i.e., start of ATI, 2 weeks after last administration).
Primary Descriptive of AEs Descriptive summary of any local and systemic AEs, including laboratory abnormalities, severity, durability, and relationship to IMP in vaccine recipients. From first administration up to week 30 (i.e., start of ATI, 2 weeks after last administration)
Secondary De novo T-cell Immunogenicity to HTI Proportion of participants who develop de-novo T-cell responses to HTI- during the intervention period as determined by IFN (gamma) ELISPOT. From week 0 to week 30
Secondary Magnitude, focus and breadth of T-cell Immunogenicity to HTI Magnitude, focus and breadth of HTI-specific T-cell responses during the intervention period as determined by IFN (gamma) ELISPOT From week 0 to week 30
Secondary B-cell Immunogenicity (serum titers of NAbs) Serum titers of autologous neutralizing antibodies (NAbs) during the intervention period From week 0 to week 30
Secondary B-cell Immunogenicity (proportion of NAbs) Proportion of participants with autologous NAbs during the intervention period From week 0 to week 30
Secondary B-cell Immunogenicity (magnitude of trimer binding antibodies) Magnitude of trimer binding antibodies during the intervention period From week 0 to week 30
Secondary B-cell Immunogenicity (proportion of trimer binding antibodies) Proportion of participants with a trimer binding antibody response during the intervention period From week 0 to week 30
Secondary B-cell Immunogenicity (serum titers heterologous neutralising antibodies) Serum titres of heterologous neutralising antibodies (i.e., against additional [Tier 1a/b, Tier 2] virus strains) during the intervention period From week 0 to week 30
Secondary B-cell Immunogenicity (proportion of heterologous neutralising antibodies) Proportion of participants with heterologous neutralising antibodies during the intervention period From week 0 to week 30
Secondary Viral rebound during ATI (sustained viral remission) Percentage of participants with sustained viral remission, defined as pVL <50 copies/mL at 12 and 24 weeks after ATI start, respectively At 12 and 24 weeks after ATI start
Secondary Viral rebound during ATI (time to viral detection) Time to viral detection, defined as the time from ATI start to the first occurrence of detectable pVL (=50 copies/mL). From ATI start to the first occurrence of detectable pVL pVL (from week 30 to week 54 (ATI period)
Secondary Viral rebound during ATI (post-rebound viral control) Percentage of participants with post-rebound viral control, defined as a pVL <2,000 copies/mL at 12 and 24 weeks after ATI start, respectively At 12 and 24 weeks after ATI start
Secondary Viral rebound during ATI (percentage of off-ART) Percentage of participants who remain off-ART at 12 and 24 weeks after ATI start, respectively. At 12 and 24 weeks after ATI start
Secondary Viral rebound during ATI (time off-ART) Time off-ART, defined as time from ATI start to ART resumption. From ATI start to ART resumption (from week 30 to week 54 (ATI period)
Secondary Safety of an ATI period (symptoms compatible with acute retroviral syndrome) Proportion of participants who develop symptoms compatible with acute retroviral syndrome From week 30 to week 54
Secondary Safety of an ATI period (stress/anxiety related to ATI) Proportion of participants with clinically significant changes in the ATI Psychological questionnaire suggestive of stress/anxiety related to ATI. From week 30 to week 54
Secondary Safety of an ATI period (seeking of psychological support) Proportion of participants who seek psychological support during and/or after ATI. From week 30 to week 54
Secondary Safety of post-ATI ART resumption (viral suppression) Proportion of participants who suppress pVL to <50 copies/mL 12 weeks after ART resumption. From week 54 to week 66
Secondary Safety of post-ATI ART resumption (new mutations conferring clinically-significant resistance to antiretroviral drugs) Proportion of participants who develop new mutations not present in the pre-ART viral genotype conferring clinically-significant resistance to antiretroviral drugs. In those participants not reaching viral re-suppression 12 weeks after ART resumption, an ART viral genotype will be analyzed From week 54 to week 66
See also
  Status Clinical Trial Phase
Active, not recruiting NCT02135419 - Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions Phase 3
Active, not recruiting NCT02663856 - My Smart Age With HIV: Smartphone Self-assessment of Frailty
Completed NCT02663869 - Aging With HIV at Younger vs Older Age: a Diverse Population With Distinct Comorbidity Profiles
Completed NCT02846402 - Impact of HIV Self-testing Among Female Sex Workers in Kampala, Uganda N/A
Completed NCT02659306 - Metformin Immunotherapy in HIV Infection Phase 1
Completed NCT02921516 - Growing Up: Intervening With HIV-Positive Adolescents in Resource-Poor Settings N/A
Terminated NCT02743598 - Liraglutide for HIV-associated Neurocognitive Disorder Phase 4
Completed NCT02564341 - Targeting Effective Analgesia in Clinics for HIV - Intervention N/A
Active, not recruiting NCT02302950 - A Retrospective Analysis of Raltegravir Use in Minority HIV Infected Women in Houston, Texas N/A
Completed NCT01852942 - Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV Phase 2
Completed NCT01830595 - Lactoferrin Treatment in HIV Patients Phase 2
Completed NCT02269605 - Bryostatin-1 Effect on HIV-1 Latency and Reservoir in HIV-1 Infected Patients Receiving Antiretroviral Treatment Phase 1
Terminated NCT01902186 - Bone Mineral Density Changes in HIV-positive Females With Osteopenia Switching to Raltegravir Phase 4
Terminated NCT02109224 - Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection Phase 1
Completed NCT02525146 - Birmingham Access to Care Study N/A
Completed NCT02527135 - Text Messaging to Improve HIV Testing Among Young Women in Kenya N/A
Completed NCT02118168 - Observational Study for the Extended Follow-up of the Patients Enrolled in the Therapeutic Clinical Trial ISS T-002 N/A
Completed NCT01946217 - Factors Affecting Patient Participation in AIDS Malignancy Clinical Trials Consortium Clinical Trials N/A
Active, not recruiting NCT02602418 - Neural Correlates of Working Memory Training for HIV Patients N/A
Completed NCT01702974 - Immune Reconstitution in HIV Disease (IREHIV) Phase 2